Insulet (PODD)
NASDAQ:PODD
Top Page
Insulet
(NASDAQ:PODD)
Select Model
Select Model
Rating:68Neutral
Price Target:
$260.00
▲(25.58% Upside)
Action:ReiteratedDate:03/13/26
The score is driven primarily by strong financial performance (high margins, improved cash generation, and a much less levered 2025 balance sheet) and a constructive earnings outlook with continued growth, margin expansion, and buybacks. These positives are tempered by weak technicals (price below key moving averages with negative MACD) and a premium valuation (P/E ~81) that leaves less room for execution missteps amid guidance deceleration and higher capex/interest headwinds.
Positive Factors
Recurring revenue & installed-base growth
Conversion of MDI users and strong type‑2 adoption broaden the Omnipod installed base, reinforcing a razor/razorblade revenue stream of repeat Pod purchases. Durable installed‑base growth improves revenue visibility, retention economics and lifecycle monetization over multi‑year horizons.
Negative Factors
Manufacturing quality risk
A manufacturing defect and device correction introduce regulatory and reputational risk that can persist beyond the immediate recall. Even if limited, remediation costs (up to ~$40M disclosed) and heightened scrutiny can increase ongoing QA costs, slow new patient starts and require sustained CAPEX and process controls.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue & installed-base growth
Conversion of MDI users and strong type‑2 adoption broaden the Omnipod installed base, reinforcing a razor/razorblade revenue stream of repeat Pod purchases. Durable installed‑base growth improves revenue visibility, retention economics and lifecycle monetization over multi‑year horizons.
Read all positive factors
Insulet (PODD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$14.57B
Dividend YieldN/A
Average Volume (3M)1.07M
Price to Earnings (P/E)80.9
Beta (1Y)0.75
Revenue Growth27.12%
EPS Growth-41.72%
CountryUS
Employees5,400
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.55
Shares Outstanding70,395,850
10 Day Avg. Volume837,802
30 Day Avg. Volume1,066,367
Financial Highlights & Ratios
PEG Ratio-1.96
Price to Book (P/B)13.20
Price to Sales (P/S)7.38
P/FCF Ratio52.94
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue5.43
Enterprise Value/Gross Profit7.59
Enterprise Value/Ebitda30.25
Forecast
1Y Price Target
$353.11Price Target Upside70.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)6.33
Revenue Forecast (FY)$3.31B
Insulet Business Overview & Revenue Model
Company Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days a...
How the Company Makes Money
Insulet primarily makes money by selling the Omnipod insulin delivery system through a recurring-use (“razor/razorblade”) model. The largest revenue driver is ongoing sales of disposable Pods that users replace regularly, creating repeat purchase ...
Insulet Key Performance Indicators (KPIs)
Any
Revenue by Segment
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Provides insight into which business segments are driving sales, highlighting areas of strength and potential growth within the company's operations.
Data provided by:
The Fly
The FlyInsulet Earnings Call Summary
Earnings Call Date:Feb 18, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Positive
The earnings call emphasized strong top-line growth, margin expansion, robust cash generation, broadening commercial reach (notably in type 2 and international markets), and a deep product and clinical pipeline — all supporting continued long-term growth. Near-term headwinds include tougher 2026 comps driving guidance deceleration, higher interest expense from refinancing, elevated capital spending for capacity expansion and some revenue recognition noise. Management presented these headwinds as largely explainable and addressable while reiterating significant investments in R&D, manufacturing and commercial scale to sustain leadership.Positive Updates
Sustained High Revenue Growth
Total company revenue of $784M in Q4 2025, up 29% year-over-year on a constant currency basis; full year revenue surpassed $2.7B, ~29.5%–30% YoY constant currency growth.
Negative Updates
Guidance Indicates Near-Term Growth Deceleration
2026 guidance implies deceleration vs. 2025: total Omnipod revenue growth expected 21%–23% and total company revenue 20%–22% (management cites tougher year-over-year comps including anniversarying the first full year of the U.S. type 2 launch and annualizing international launches).
Read all updates
Q4-2025 Updates
Positive
Negative
Sustained High Revenue Growth
Total company revenue of $784M in Q4 2025, up 29% year-over-year on a constant currency basis; full year revenue surpassed $2.7B, ~29.5%–30% YoY constant currency growth.
Read all positive updates
Company Guidance
Insulet guided first-quarter 2026 Omnipod revenue growth of 28%–30% and total company revenue growth of 25%–27% (with roughly +200 bps FX tailwind to both), including U.S. Omnipod growth of 24%–26% and international Omnipod growth of 37%–39% (with ~1,100 bps FX benefit to international); for full-year 2026 the company expects Omnipod revenue to grow 21%–23% and total company revenue to grow 20%–22% (with a ~100 bps favorable FX impact), U.S. Omnipod growth of 20%–22% and international Omnipod growth of 24%–26% (reported FX benefit ~300 bps), while driving roughly 100 basis points of operating margin expansion, net interest expense of about $40 million, a non‑GAAP tax rate of 22%–23%, an adjusted EPS increase of more than 25%, a Board‑approved $350 million buyback (about $300 million to be deployed in Q1) targeting an ending diluted share count near 70 million, and free cash flow roughly flat to 2025 (partially offset by higher capex to expand manufacturing).Insulet Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.71B | 2.07B | 1.70B | 1.31B | 1.10B |
| Gross Profit | 1.94B | 1.45B | 1.16B | 805.60M | 752.10M |
| EBITDA | 586.90M | 423.70M | 323.60M | 109.00M | 139.60M |
| Net Income | 247.10M | 418.30M | 206.30M | 4.60M | 16.80M |
Balance Sheet | |||||
| Total Assets | 3.19B | 3.09B | 2.59B | 2.25B | 2.05B |
| Cash, Cash Equivalents and Short-Term Investments | 716.10M | 953.40M | 704.20M | 674.70M | 791.60M |
| Total Debt | 1.05B | 1.42B | 1.45B | 1.43B | 1.29B |
| Total Liabilities | 1.68B | 1.88B | 1.86B | 1.77B | 1.49B |
| Stockholders Equity | 1.52B | 1.21B | 732.70M | 476.40M | 556.30M |
Cash Flow | |||||
| Free Cash Flow | 377.70M | 305.40M | 70.10M | -38.30M | -190.80M |
| Operating Cash Flow | 569.30M | 430.30M | 145.70M | 119.00M | -68.10M |
| Investing Cash Flow | -222.70M | -146.20M | -119.40M | -191.10M | -82.70M |
| Financing Cash Flow | -595.30M | -28.10M | -13.60M | -40.30M | 40.70M |
Insulet Technical Analysis
Negative
207.04
Price Trends
241.94
Negative
272.90
Negative
293.39
Negative
Market Momentum
-10.13
Positive
27.80
Positive
14.14
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 207.04 is below the 20-day moving average (MA) of 225.61, below the 50-day MA of 241.94, and below the 200-day MA of 293.39, indicating a bearish trend. The MACD of -10.13 indicates Positive momentum. The RSI at 27.80 is Positive, neither overbought nor oversold. The STOCH value of 14.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.
Insulet Risk Analysis
Insulet disclosed 36 risk factors in its most recent earnings report. Insulet reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Insulet Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $24.00B | 30.97 | 32.44% | ― | 14.21% | 5.66% | |
69 Neutral | $21.57B | 32.31 | 10.21% | 0.94% | 5.15% | 60.30% | |
68 Neutral | $14.57B | 80.92 | 17.36% | ― | 27.12% | -41.72% | |
65 Neutral | $17.81B | 25.25 | 5.60% | 1.05% | 5.47% | -23.03% | |
64 Neutral | $25.92B | 24.78 | 8.21% | 3.30% | -0.76% | -55.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.29B | -7.22 | -141.98% | ― | 17.87% | -57.03% |
* Healthcare Sector Average
PODD
Insulet
207.04
-49.76
-19.38%
DXCM
Dexcom
62.37
0.57
0.92%
PHG
Koninklijke Philips
27.29
4.15
17.92%
STE
Steris
219.94
0.72
0.33%
ZBH
Zimmer Biomet Holdings
91.03
-20.46
-18.35%
TNDM
Tandem Diabetes Care
18.81
1.15
6.51%
Insulet Corporate Events
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Insulet Issues Voluntary Omnipod 5 Device Correction
Negative
Mar 12, 2026
On March 12, 2026, Insulet initiated a voluntary medical device correction in the U.S. for specific lots of its Omnipod 5 Pods after product monitoring identified a manufacturing issue that can cause a tear in internal tubing and lead to underR...
Executive/Board ChangesRegulatory Filings and Compliance
Insulet Finalizes Severance Terms for Departing CFO
Neutral
Mar 4, 2026
On February 27, 2026, Insulet Corporation entered into a severance agreement with former Chief Financial Officer Ana M. Chadwick that aligns fully with previously disclosed executive compensation and severance arrangements. The agreement formalize...
Business Operations and StrategyStock BuybackFinancial Disclosures
Insulet Posts Strong Q4 Results, Expands Share Repurchase Program
Positive
Feb 18, 2026
Insulet reported strong fourth-quarter and full-year 2025 results on February 18, 2026, with revenue up about 31% for both periods and constant-currency growth of roughly 29% to 30%, marking a 10th straight year of at least 20% constant-currency r...
Business Operations and Strategy
Insulet Extends Key Supply Agreement with NXP USA
Positive
Feb 3, 2026
On January 29, 2026, Insulet Corporation and NXP USA, Inc. entered into a 2026 Addendum, effective January 1, 2026, that extends the term of their existing 2017 purchase agreement and revises conditions related to pricing, product volume, and orde...
Business Operations and StrategyExecutive/Board Changes
Insulet Revises Annual Incentive Plan for 2026
Neutral
Dec 17, 2025
Insulet announced amendments to its Annual Incentive Plan effective January 1, 2026, with revisions that impact terms regarding termination, retirement eligibility for prorated awards, compensation recoupment, and award limits. These changes aim t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.